Vir Biotechnology, Inc. (NASDAQ:VIR) Director Sells $16,160.00 in Stock

Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) Director Janet Napolitano sold 3,200 shares of Vir Biotechnology stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $5.05, for a total transaction of $16,160.00. Following the completion of the sale, the director now directly owns 16,416 shares of the company's stock, valued at approximately $82,900.80. This trade represents a 16.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Vir Biotechnology Price Performance

VIR traded down $0.05 during trading on Thursday, hitting $5.23. 561,398 shares of the stock traded hands, compared to its average volume of 1,398,535. The firm has a 50-day moving average of $5.41 and a 200 day moving average of $7.45. Vir Biotechnology, Inc. has a 12-month low of $4.32 and a 12-month high of $14.45. The firm has a market capitalization of $722.98 million, a P/E ratio of -1.33 and a beta of 1.24.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.88) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.05). The firm had revenue of $3.03 million for the quarter, compared to the consensus estimate of $8.59 million. Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. The firm's revenue for the quarter was down 94.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.48) earnings per share. As a group, equities analysts predict that Vir Biotechnology, Inc. will post -3.92 EPS for the current fiscal year.

Institutional Trading of Vir Biotechnology

Several large investors have recently added to or reduced their stakes in VIR. Barclays PLC lifted its holdings in Vir Biotechnology by 1.3% during the third quarter. Barclays PLC now owns 550,186 shares of the company's stock valued at $4,121,000 after purchasing an additional 7,287 shares in the last quarter. KBC Group NV lifted its holdings in shares of Vir Biotechnology by 136.5% in the fourth quarter. KBC Group NV now owns 8,970 shares of the company's stock worth $66,000 after buying an additional 5,177 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Vir Biotechnology by 11.1% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 29,202 shares of the company's stock worth $214,000 after buying an additional 2,922 shares in the last quarter. abrdn plc purchased a new position in shares of Vir Biotechnology in the fourth quarter worth $2,666,000. Finally, State of Alaska Department of Revenue lifted its holdings in shares of Vir Biotechnology by 33.0% in the fourth quarter. State of Alaska Department of Revenue now owns 202,441 shares of the company's stock worth $1,485,000 after buying an additional 50,199 shares in the last quarter. 65.32% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. HC Wainwright reiterated a "buy" rating and issued a $110.00 target price on shares of Vir Biotechnology in a research note on Friday, February 28th. Barclays boosted their price target on shares of Vir Biotechnology from $26.00 to $31.00 and gave the company an "overweight" rating in a research report on Friday, February 28th. Needham & Company LLC reaffirmed a "buy" rating and set a $14.00 target price on shares of Vir Biotechnology in a report on Thursday, May 22nd. Finally, The Goldman Sachs Group decreased their target price on shares of Vir Biotechnology from $28.00 to $21.00 and set a "buy" rating on the stock in a report on Thursday, April 17th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. According to data from MarketBeat.com, Vir Biotechnology presently has a consensus rating of "Moderate Buy" and a consensus target price of $32.86.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).